Chinese Fibromyalgia Market Research Report- Forecast to 2022

Chinese Fibromyalgia Market Research Report- Forecast to 2022

ID: MRFR/HC/4175-CRR | March, 2018 | Region: Global | 85 pages | Cooked Research Reports

Chinese Fibromyalgia Market Research Report: By Diagnosis (Laboratory Evaluation, Presence Of Central Sensitization), Treatment (Targeted (Antidepressants, Anti-Seizure Drugs), Symptomatic Treatment, End Users (Hospitals &Clinics) - Forecast Till 2022  


 


Market Scenario


Fibromyalgia syndrome is a condition characterized by widespread musculoskeletal pain. Patients with fibromyalgia may also have muscle stiffness, increased sensitivity to pain, problems with mental processes, fatigue, irritable bowel syndrome (IBS), and others. As symptoms of fibromyalgia syndrome mimic other chronic diseases, therefore its diagnosis takes a long time. According to a study published in Arthritis Research & Therapy journal in 2017, in Taiwan, the risk of coronary heart disease in fibromyalgia patients was 47% higher than in the general population. For fibromyalgia to be diagnosed, the differential diagnosis is most commonly used.  Other diagnostic procedures, such as laboratory evaluations are also used.


Notably, increasing cases of rheumatic diseases and growing geriatric population are the key factors driving the Chinese fibromyalgia market. According to the study published in Aging Clinical and Experimental Research in 2014, fibromyalgia syndrome can affect people of all age group, with the high prevalence in the elderly population as the geriatric population is more vulnerable towards pain, reduced mobility, and sleep disruption. In the general population, the prevalence of fibromyalgia increases by 2% at the age of 20 to 8% at the age of 70.


Growing awareness among the population, and rising incidences of traumatic stress and road accidents are also fueling the market growth. According to a study published in Pain Research and Management journal, in 2014, it was found that physical trauma is followed by fibromyalgia syndrome. In this study, conducted with a specific cohort of individuals involved in a motor vehicle collision, found that 8% of individuals developed widespread chronic pain. Widespread chronic pain characterizes fibromyalgia.


However, difficulty in diagnosis may hinder the growth of the market over the forecast period. Fibromyalgia can’t be easily confirmed as the condition is commonly expressed with many other accompanying chronic disorders such as rheumatic diseases, neurological disorders, mental health problems, and others


Chinese fibromyalgia market is expected to grow at a CAGR of 18.7% during the forecast period 2017-2022.


Intended Audience



  • Pharmaceutical Companies

  • Hospitals & Clinics

  • Research and Development (R&D) Companies

  • Government Research Institute

  • Academic Institutes and Universities


Figure: Chinese Fibromyalgia Market by Diagnosis market share, 2016 (%)


  Fibromyalgia Market by Diagnosis


Sources: Annual reports, Press release, White paper, Company presentation


Segmentation


The Chinese fibromyalgia market is segmented on the basis of diagnosis, treatment, and end-user.


On the basis of the diagnosis, the market is classified into laboratory evaluation and presence of central sensitization.


On the basis of the treatment, the market is segmented into targeted treatment and symptomatic treatment.


On the basis of the end-users, the market is segmented into hospitals, clinics, diagnostic centers, and others.


Research Methodology


 Fibromyalgia Market by Diagnosis Research Methodology


Sources: Annual reports, Press release, White paper, and Company presentation


Key Findings



  • The Chinese fibromyalgia market is expected to reach USD 3,079.1 million by 2022 at a CAGR of 18.7%

  • On the basis of the diagnosis, the laboratory evaluation segment is expected to command the largest market share of 77.2% over the review period, and it is also expected to grow at the fastest CAGR of 19.1% during the forecast period 2017-2022

  • On the basis of the treatment, the symptomatic treatment segment is expected to command the largest market share of 68.6% over the review period, and targeted treatment is expected to grow at the fastest CAGR of 19.2% during the forecast period 2017-2022

  • South Central China holds the largest share of the Chinese fibromyalgia market and is expected to reach USD 785.3 million by 2022

  • North China is the fastest growing market, which is expected to grow at a CAGR of 19.2% over the forecast period 2017-2022


Regional Analysis


South Central China accounted for the major share of the market owing to the rising prevalence of fibromyalgia in this region. Rising cases of chronic rheumatic diseases are also capable of fuelling the fibromyalgia market in China. Prevalence of rheumatoid arthritis is around 0.35%, with the significantly higher rate in Northern China as compared to the Southern part.


The rising healthcare expenditure is also propelling the growth of the market. In China, the total expenditure on health per capita in 2014 was USD 731, as per the World Health Organization (WHO) in 2015. The health expenditure in China grew at a rate of 11.6% per year, suggested by a study published in BMC Health Services Research journal in 2017. This rate is much faster than the growth of the country’s economy, i.e. 9.9% per year.


Key Players


Some of key the players in the market are Pfizer, GlaxoSmithKline, AstraZeneca, Roche, Astellas Pharma, Eli Lilly and Company, Johnson & Johnson Services, Inc., SANOFI, Bayer AG, AbbVie, ALLERGAN, Boehringer Ingelheim, Cephalon, Inc., Vertical Pharmaceuticals, Sunovion Pharms Inc, Jazz Pharmaceuticals, ABBOTT, NOVARTIS, and others.

License
Single User Enterprise User (Buy Premium Reports Chapterwise)
Currency
TABLE OF CONTENTS

2.1 Research Objective 12

2.2 Assumptions & Limitations 12

2.2.1 Assumptions 12

2.2.2 Limitations 12

3.1 Research Process 14

3.2 Primary Research 15

3.3 Secondary Research 15

3.4 Market Size Estimation 15

4.1 Introduction 18

4.2 Drivers 19

4.2.1 Rising Incidences of Traumatic Stress and Road Accidents 19

4.2.2 Increasing Cases of Rheumatic Diseases 20

4.2.3 Growing Awareness among the population 21

4.2.4 Increasing geriatric population 22

4.3 Restraints 23

4.3.1 Difficulty in Diagnosis 23

4.4 Opportunities 24

4.4.1 Unmet Medical Need in Fibromyalgia Treatment 24

4.5 Mega Trends 24

4.5.1 Chinese Treatment Options 24

4.5.2 Pipeline Drugs 24

4.6 Macroeconomic Indicators 25

5.1 Value Chain Analysis 27

5.1.1 R&D 27

5.1.2 Manufacturing 27

5.1.3 Distribution & Sales 27

5.1.4 Post-Sales Monitoring 28

5.2 Porter’s Five Forces Model 28

5.2.1 Bargaining Power of Suppliers 29

5.2.2 Bargaining Power of Buyers 29

5.2.3 Threat of New Entrant 29

5.2.4 Threat of Substitute 29

5.2.5 Intensity of Rivalry 29

5.3 Demand & Supply: Gap Analysis 30

5.4 Pricing Analysis 30

5.5 Investment Opportunity Analysis 30

6.1 Introduction 32

6.2 Laboratory Evaluation 33

6.3 Presence of Central Sensitization 34

7.1 Introduction 36

7.2 Introduction 37

7.3 Targeted Treatment 38

7.4 Symptomatic treatment 39

8.1 Introduction 41

8.2 Hospitals 42

8.3 Clinics 42

8.4 Diagnostic Centers 43

9.1 Introduction 45

9.2 North China 46

9.3 Northwest China 47

9.4 East China 49

9.5 South Central China 50

9.6 South West China 52

10.1 Introduction 55

11.1 Pfizer 57

11.1.1 Financials 57

11.1.2 Products 57

11.1.3 Strategy 57

11.1.4 Key Developments 57

11.2 GlaxoSmithKline 58

11.2.1 Financials 58

11.2.2 Products 58

11.2.3 Strategy 58

11.2.4 Key Developments 58

11.3 AstraZeneca 59

11.3.1 Financials 59

11.3.2 Products 59

11.3.3 Strategy 59

11.3.4 Key Developments 59

11.4 Roche 60

11.4.1 Financials 60

11.4.2 Products 60

11.4.3 Strategy 60

11.4.4 Key Developments 60

11.5 Astellas Pharma 61

11.5.1 Financials 61

11.5.2 Products 61

11.5.3 Strategy 61

11.5.4 Key Developments 61

11.6 Eli Lilly and Company 62

11.6.1 Financials 62

11.6.2 Products 62

11.6.3 Strategy 62

11.6.4 Key Developments 62

11.7 Johnson & Johnson 63

11.7.1 Financials 63

11.7.2 Products 63

11.7.3 Strategy 63

11.7.4 Key Developments 63

11.8 SANOFI 64

11.8.1 Financials 64

11.8.2 Products 64

11.8.3 Strategy 64

11.8.4 Key Developments 64

11.9 Bayer 65

11.9.1 Financials 65

11.9.2 Products 65

11.9.3 Strategy 65

11.9.4 Key Developments 65

11.10 AbbVie 66

11.10.1 Financials 66

11.10.2 Products 66

11.10.3 Strategy 66

11.10.4 Key Developments 66

11.11 ALLERGAN 67

11.11.1 Financials 67

11.11.2 Products 67

11.11.3 Strategy 67

11.11.4 Key Developments 67

12.1 Key Findings 69

12.1.1 From CEO’s View Point 69

12.2 Key companies to watch 69

13.1 Discussion Blue Print 71

TABLE 1 MARKET SYNOPSIS 10

TABLE 2 CHINESE FIBROMYALGIA MARKET, BY DIAGNOSIS 2014-2022 (USD MILLION) 32

TABLE 3 CHINESE FIBROMYALGIA MARKET FOR LABORATORY EVALUATION 2014-2022 (USD MILLION) 33

TABLE 4 CHINESE FIBROMYALGIA MARKET FOR PRESENCE OF CENTRAL SENSITIZATION 2014-2022 (USD MILLION) 34

TABLE 5 GLOBAL FIBROMYALGIA MARKET, BY TREATMENT 2014-2022 (USD MILLION) 36

TABLE 6 CHINESE FIBROMYALGIA MARKET, BY TREATMENT 2014-2022 (USD MILLION) 37

TABLE 7 CHINESE FIBROMYALGIA MARKET FOR TARGETED TREATMENT 2014-2022 (USD MILLION) 38

TABLE 8 CHINESE FIBROMYALGIA MARKET FOR SYMPTOMATIC TREATMENT 2014-2022 (USD MILLION) 39

TABLE 9 CHINESE FIBROMYALGIA MARKET, BY END USER 2014-2022 (USD MILLION) 41

TABLE 10 CHINESE FIBROMYALGIA MARKET FOR HOSPITALS 2014-2022 (USD MILLION) 42

TABLE 11 CHINESE FIBROMYALGIA MARKET FOR CLINICS 2014-2022 (USD MILLION) 42

TABLE 12 CHINESE FIBROMYALGIA MARKET FOR DIAGNOSTIC CENTERS 2014-2022 (USD MILLION) 43

TABLE 13 CHINESE FIBROMYALGIA MARKET, BY REGIONS 2014-2022 (USD MILLION) 45

TABLE 14 NORTH CHINA CHINESE FIBROMYALGIA MARKET, BY DIAGNOSIS 2014-2022 (USD MILLION) 46

TABLE 15 NORTH CHINA CHINESE FIBROMYALGIA MARKET, BY TREATMENT 2014-2022 (USD MILLION) 46

TABLE 16 NORTH CHINA CHINESE FIBROMYALGIA MARKET, BY END USER 2014-2022 (USD MILLION) 47

TABLE 17 NORTHWEST CHINA CHINESE FIBROMYALGIA MARKET, BY DIAGNOSIS 2014-2022 (USD MILLION) 47

TABLE 18 NORTHWEST CHINA CHINESE FIBROMYALGIA MARKET, BY TREATMENT 2014-2022 (USD MILLION) 48

TABLE 19 NORTHWEST CHINA CHINESE FIBROMYALGIA MARKET, BY END USER 2014-2022 (USD MILLION) 48

TABLE 20 EAST CHINA CHINESE FIBROMYALGIA MARKET, BY DIAGNOSIS 2014-2022 (USD MILLION) 49

TABLE 21 EAST CHINA CHINESE FIBROMYALGIA MARKET, BY TREATMENT 2014-2022 (USD MILLION) 49

TABLE 22 EAST CHINA CHINESE FIBROMYALGIA MARKET, BY END USER 2014-2022 (USD MILLION) 50

TABLE 23 SOUTH CENTRAL CHINA CHINESE FIBROMYALGIA MARKET, BY DIAGNOSIS 2014-2022 (USD MILLION) 50

TABLE 24 SOUTH CENTRAL CHINA CHINESE FIBROMYALGIA MARKET, BY TREATMENT 2014-2022 (USD MILLION) 51

TABLE 25 SOUTH CENTRAL CHINA CHINESE FIBROMYALGIA MARKET, BY END USER 2014-2022 (USD MILLION) 51

TABLE 26 SOUTH WEST CHINA CHINESE FIBROMYALGIA MARKET, BY DIAGNOSIS 2014-2022 (USD MILLION) 52

TABLE 27 SOUTH WEST CHINA CHINESE FIBROMYALGIA MARKET, BY TREATMENT 2014-2022 (USD MILLION) 52

TABLE 28 SOUTH WEST CHINA CHINESE FIBROMYALGIA MARKET, BY END USER 2014-2022 (USD MILLION) 53

FIGURE 1 MARKET STRUCTURE 12

FIGURE 2 RESEARCH PROCESS 14

FIGURE 3 VALUE CHAIN: CHINESE FIBROMYALGIA MARKET 27

FIGURE 4 PORTERS FIVE FORCES ANALYSIS: CHINESE FIBROMYALGIA MARKET 28

FIGURE 5 CHINESE FIBROMYALGIA MARKET, BY DIAGNOSIS 2016 & 2022 (USD MILLION) 33

FIGURE 6 GLOBAL FIBROMYALGIA MARKET, BY TREATMENT 2016 & 2022 (USD MILLION) 36

FIGURE 7 CHINESE FIBROMYALGIA MARKET, BY TREATMENT 2016 & 2022 (USD MILLION) 38

FIGURE 8 CHINESE FIBROMYALGIA MARKET, BY END USER 2016 & 2022 (USD MILLION) 41

FIGURE 9 CHINA FIBROMYALGIA MARKET SHARE, BY REGION MARKET, 2016 (%) 45

FIGURE 10 CHINA FIBROMYALGIA MARKET SHARE ANALYSIS, 2016 (%) 55